Research programme: kallikrein inhibitors - IBEX

Drug Profile

Research programme: kallikrein inhibitors - IBEX

Latest Information Update: 14 Apr 2011

Price : $50

At a glance

  • Originator IBEX Technologies
  • Class
  • Mechanism of Action Kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Ovarian cancer; Prostate cancer

Most Recent Events

  • 12 Jan 2005 Preclinical trials in Prostate cancer in Canada (unspecified route)
  • 12 Jan 2005 Preclinical trials in Ovarian cancer in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top